- Home
- ANAB vs BCSF Comparison
ANAB vs BCSF Comparison
Compare ANAB & BCSF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ANAB
- BCSF
- Stock Information
- Founded
- ANAB 2005
- BCSF 2015
- Country
- ANAB United States
- BCSF United States
- Employees
- ANAB N/A
- BCSF N/A
- Industry
- ANAB Biotechnology: Pharmaceutical Preparations
- BCSF Finance/Investors Services
- Sector
- ANAB Health Care
- BCSF Finance
- Exchange
- ANAB Nasdaq
- BCSF Nasdaq
- Market Cap
- ANAB 1.0B
- BCSF 901.0M
- IPO Year
- ANAB 2017
- BCSF 2018
- Fundamental
- Price
- ANAB $42.39
- BCSF $14.36
- Analyst Decision
- ANAB Buy
- BCSF Buy
- Analyst Count
- ANAB 12
- BCSF 2
- Target Price
- ANAB $63.80
- BCSF $15.50
- AVG Volume (30 Days)
- ANAB 735.4K
- BCSF 428.0K
- Earning Date
- ANAB 11-04-2025
- BCSF 11-10-2025
- Dividend Yield
- ANAB N/A
- BCSF 12.61%
- EPS Growth
- ANAB N/A
- BCSF N/A
- EPS
- ANAB N/A
- BCSF 1.44
- Revenue
- ANAB $169,467,000.00
- BCSF $278,347,000.00
- Revenue This Year
- ANAB $37.52
- BCSF N/A
- Revenue Next Year
- ANAB N/A
- BCSF N/A
- P/E Ratio
- ANAB N/A
- BCSF $9.92
- Revenue Growth
- ANAB 196.42
- BCSF N/A
- 52 Week Low
- ANAB $12.21
- BCSF $13.20
- 52 Week High
- ANAB $43.31
- BCSF $19.21
- Technical
- Relative Strength Index (RSI)
- ANAB 71.33
- BCSF 58.07
- Support Level
- ANAB $33.10
- BCSF $13.91
- Resistance Level
- ANAB $43.31
- BCSF $14.22
- Average True Range (ATR)
- ANAB 2.88
- BCSF 0.31
- MACD
- ANAB 0.51
- BCSF 0.07
- Stochastic Oscillator
- ANAB 91.49
- BCSF 96.81
About ANAB AnaptysBio Inc.
AnaptysBio Inc is a clinical-stage biotechnology company. The company is focused on developing antibody product candidates for unmet medical needs in inflammation and immuno-oncology. The company is developing immune cell modulating antibodies, including two wholly owned checkpoint agonists in clinical-stage development, for autoimmune and inflammatory diseases; rosnilimab, PD-1 agonist in a Phase 2b trial for the treatment of moderate-to-severe rheumatoid arthritis (RA) and a Phase 2 trial for the treatment of moderate-to-severe ulcerative colitis (UC); and ANB032, BTLA agonist, in a Phase 2b trial for the treatment of moderate-to-severe atopic dermatitis (AD).
About BCSF Bain Capital Specialty Finance Inc.
Bain Capital Specialty Finance Inc is an externally managed, closed-end, non-diversified management investment company. The company's objective is to provide risk-adjusted returns and current income to investors by investing predominantly in middle-market companies with between $10.0 million and $150.0 million in annual EBITDA. Its portfolio of investments includes First Lien Senior Secured Loan, Preferred Equity, Equity Interest, Warrants, and Second Lien Senior Secured Loan among others.